Literature DB >> 19142298

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Macarthur Charles1, Francine Noel, Paul Leger, Patrice Severe, Cynthia Riviere, Carole Anne Beauharnais, Erica Miller, John Rutledge, Heejung Bang, Wesley Shealey, Richard T D'Aquila, Roy M Gulick, Warren D Johnson, Peter F Wright, Jean William Pape, Daniel W Fitzgerald.   

Abstract

OBJECTIVE: To assess outcomes after antiretroviral therapy (ART) in adolescents and youth in Haiti, a country with a generalized epidemic of infection with HIV-1.
METHODS: An assessment was made of survival, plasma HIV-1 ribonucleic acid (RNA) concentrations and HIV-1 drug resistance patterns after 12 months of ART in patients aged 13-25 years who presented to a clinic in Port-au-Prince, Haiti, with AIDS between 1 March 2003 and 31 December 2005. Participants received ART in accordance with WHO guidelines. Kaplan-Meier analysis was used to estimate survival probabilities and their 95% confidence intervals (CI) for the period from ART initiation to death.
FINDINGS: Of a total of 146 patients, 96 (66%) were female; the median CD4+ T-cell count at baseline was 129 cells/ml. By Kaplan-Meier analysis, 13% of the patients had died at 12 months, 17% at 24 months and 20% at 36 months. A plasma HIV-1 RNA concentration > or = 50 copies/ml was seen in 40 (51%) of 79 patients 12 months after treatment initiation and was associated with poor ART adherence. Among 29 patients with > 1000 copies/ml at 12 months, resistance mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs) were detected in 23 cases (79%); to both NNRTIs and lamivudine in 21 (72%) cases; and to NNRTIs, lamivudine and other nucleoside reverse transcriptase inhibitors in 10 (35%) cases. One hundred and six participants (73%) reported sexual intercourse without condoms, and 35 of the 96 women (36%) were pregnant during follow-up.
CONCLUSION: Adolescents and youth with AIDS receiving ART are at risk of virologic failure and disease progression and can therefore transmit HIV-1 to sexual partners and infants. Strategies to target the special needs of this age group are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19142298      PMCID: PMC2649577          DOI: 10.2471/blt.07.050120

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  45 in total

1.  Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.

Authors:  D A Murphy; C M Wilson; S J Durako; L R Muenz; M Belzer
Journal:  AIDS Care       Date:  2001-02

2.  Community-based approaches to HIV treatment in resource-poor settings.

Authors:  P Farmer; F Léandre; J S Mukherjee; M Claude; P Nevil; M C Smith-Fawzi; S P Koenig; A Castro; M C Becerra; J Sachs; A Attaran; J Y Kim
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

3.  Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.

Authors:  M Badri; R Ehrlich; R Wood; T Pulerwitz; G Maartens
Journal:  Int J Tuberc Lung Dis       Date:  2001-03       Impact factor: 2.373

4.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Anaemia in schoolchildren in eight countries in Africa and Asia.

Authors:  A Hall; E Bobrow; S Brooker; M Jukes; K Nokes; J Lambo; H Guyatt; D Bundy; S Adjei; S T Wen; H Subagio; M Z Rafiluddin; T Miguel; S Moulin; J de Graft Johnson; M Mukaka; N Roschnik; M Sacko; A Zacher; B Mahumane; C Kihamia; L Mwanri; S Tatala; N Lwambo; J Siza; L N Khanh; H H Khoi; N D Toan
Journal:  Public Health Nutr       Date:  2001-06       Impact factor: 4.022

6.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

7.  Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Authors:  S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

8.  Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.

Authors:  C C Whalen; P Nsubuga; A Okwera; J L Johnson; D L Hom; N L Michael; R D Mugerwa; J J Ellner
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

9.  Antiretroviral therapy for HIV-1-infected children in Haiti.

Authors:  Erik George; Francine Noël; Gyrlande Bois; Rachelle Cassagnol; Louise Estavien; Patricia De Matteis Rouzier; Rose I Verdier; Warren D Johnson; Jean W Pape; Daniel W Fitzgerald; Peter F Wright
Journal:  J Infect Dis       Date:  2007-04-03       Impact factor: 5.226

10.  Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.

Authors:  D W Fitzgerald; M Desvarieux; P Severe; P Joseph; W D Johnson; J W Pape
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

View more
  25 in total

1.  Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count?

Authors:  Rashida Ferrand; Sara Lowe; Barbra Whande; Lucia Munaiwa; Lisa Langhaug; Frances Cowan; Owen Mugurungi; Diana Gibb; Shungu Munyati; Brian G Williams; Elizabeth L Corbett
Journal:  Bull World Health Organ       Date:  2009-12-16       Impact factor: 9.408

2.  Applying the information-motivation-behavioral skills model in medication adherence among Thai youth living with HIV: a qualitative study.

Authors:  Chokechai Rongkavilit; Sylvie Naar-King; Linda M Kaljee; Apirudee Panthong; Juline A Koken; Torsak Bunupuradah; Jeffrey T Parsons
Journal:  AIDS Patient Care STDS       Date:  2010-11-22       Impact factor: 5.078

3.  Successes and challenges of HIV treatment programs in Haiti: aftermath of the earthquake.

Authors:  S Koenig; Lc Ivers; S Pace; R Destine; F Leandre; R Grandpierre; J Mukherjee; Pe Farmer; Jw Pape
Journal:  HIV Ther       Date:  2010-03

4.  An EMR-Based Alert with Brief Provider-Led ART Adherence Counseling: Promising Results of the InfoPlus Adherence Pilot Study Among Haitian Adults with HIV Initiating ART.

Authors:  Nancy Puttkammer; Jane M Simoni; Tracy Sandifer; Jean Marcxime Chéry; Witson Dervis; Jean Gabriel Balan; Jean Geto Dubé; Guirlaine Calixte; Ermane Robin; Kesner François; Cameron Casey; Ira Wilson; Jean Guy Honoré
Journal:  AIDS Behav       Date:  2020-12

5.  Disclosure of their HIV status to perinatally infected youth using the adapted Blasini disclosure model in Haiti and the Dominican Republic: preliminary results.

Authors:  Consuelo M Beck-Sagué; Jessy Dévieux; Maria Claudia Pinzón-Iregui; Leonel Lerebours-Nadal; Rosa Abreu-Pérez; Rachel Bertrand; Vanessa Rouzier; Stephanie Gaston; Gladys Ibanez; Mina Halpern; Jean W Pape; Patricia Dorceus; Sharice M Preston; Andrew G Dean; Stephen W Nicholas; Ileana Blasini
Journal:  AIDS       Date:  2015-06       Impact factor: 4.177

Review 6.  Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review.

Authors:  James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan
Journal:  Bull World Health Organ       Date:  2013-02-21       Impact factor: 9.408

Review 7.  Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges.

Authors:  Elizabeth D Lowenthal; Sabrina Bakeera-Kitaka; Tafireyi Marukutira; Jennifer Chapman; Kathryn Goldrath; Rashida A Ferrand
Journal:  Lancet Infect Dis       Date:  2014-01-07       Impact factor: 25.071

8.  Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.

Authors:  Sarah B Lorenzana; Michael D Hughes; Beatriz Grinsztejn; Ann C Collier; Paula Mendes Luz; Kenneth A Freedberg; Robin Wood; Julie H Levison; Peter N Mugyenyi; Robert Salata; Carole L Wallis; Milton C Weinstein; Robert T Schooley; Rochelle P Walensky
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

9.  Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti.

Authors:  Edva Noel; Morgan Esperance; Megan McLaughlin; Rachel Bertrand; Jessy Devieux; Patrice Severe; Diessy Decome; Adias Marcelin; Janet Nicotera; Chris Delcher; Mark Griswold; Genevive Meredith; Jean William Pape; Serena P Koenig
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

10.  Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces.

Authors:  Geoffrey Fatti; Ashraf Grimwood; Peter Bock
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.